FIRST-IN-HUMAN PHASE 1 STUDY OF TORL-1-23, A NOVEL CLAUDIN 6 (CLDN6) TARGETED ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH OVARIAN CANCER

被引：0

作者：

Konecny, Gottfried ^{[1
]}

Hendrickson, Andrea Wahner ^{[2
]}

Winterhoff, Boris ^{[3
]}

Chander, Cinthiya ^{[1
]}

Bilic, Sanela ^{[4
]}

Davenport, Simon ^{[5
]}

Chung, Adrine ^{[6
]}

Miller, Lei-Lani ^{[6
]}

Press, Michael ^{[5
]}

Letrent, Stephen ^{[7
]}

Slamon, Dennis ^{[8
]}

机构：

[1] UCLA, Obstet & Gynecol, Los Angeles, CA USA

[2] Mayo Clin, 200 First St Sw, Rochester, MN USA

[3] Univ Minnesota, Div Gynecol Oncol, Minneapolis, MN USA

[4] Vanadro, Pharmacol, Urbandale, IA USA

[5] Univ Southern Calif, Dept Pathol, Los Angeles, CA USA

[6] Translat Res Oncol US, Clin Operat, Los Angeles, CA USA

[7] TORL Biotherapeut, Clin Dev, Culver City, CA USA

[8] Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA

来源：

关键词：

D O I：

10.1136/ijgc-2023-IGCS.102

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PR062

引用

页码：A67 / A67

页数：1